Your browser doesn't support javascript.
loading
Characterization of white matter hyperintensities in Down syndrome.
Morcillo-Nieto, Alejandra O; Zsadanyi, Sara E; Arriola-Infante, Jose E; Carmona-Iragui, Maria; Montal, Victor; Pegueroles, Jordi; Aranha, Mateus Rozalem; Vaqué-Alcázar, Lídia; Padilla, Concepción; Benejam, Bessy; Videla, Laura; Barroeta, Isabel; Fernandez, Susana; Altuna, Miren; Giménez, Sandra; González-Ortiz, Sofía; Bargalló, Núria; Ribas, Laia; Arranz, Javier; Torres, Soraya; Iulita, Maria Florencia; Belbin, Olivia; Camacho, Valle; Alcolea, Daniel; Lleó, Alberto; Fortea, Juan; Bejanin, Alexandre.
Afiliação
  • Morcillo-Nieto AO; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Zsadanyi SE; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Arriola-Infante JE; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Carmona-Iragui M; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Montal V; Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Pegueroles J; Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain.
  • Aranha MR; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Vaqué-Alcázar L; Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Padilla C; Barcelona Supercomputing Center, Barcelona, Spain.
  • Benejam B; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Videla L; Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Barroeta I; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Fernandez S; Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Altuna M; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Giménez S; Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • González-Ortiz S; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Bargalló N; Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Ribas L; Estudis de Ciències de la Salut, Universitat Oberta de Catalunya, Barcelona, Spain.
  • Arranz J; Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain.
  • Torres S; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Iulita MF; Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Belbin O; Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain.
  • Camacho V; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Alcolea D; Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Lleó A; Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain.
  • Fortea J; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Bejanin A; Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
Alzheimers Dement ; 20(9): 6527-6541, 2024 Sep.
Article em En | MEDLINE | ID: mdl-39087352
ABSTRACT

INTRODUCTION:

In Down syndrome (DS), white matter hyperintensities (WMHs) are highly prevalent, yet their topography and association with sociodemographic data and Alzheimer's disease (AD) biomarkers remain largely unexplored.

METHODS:

In 261 DS adults and 131 euploid controls, fluid-attenuated inversion recovery magnetic resonance imaging scans were segmented and WMHs were extracted in concentric white matter layers and lobar regions. We tested associations with AD clinical stages, sociodemographic data, cerebrospinal fluid (CSF) AD biomarkers, and gray matter (GM) volume.

RESULTS:

In DS, total WMHs arose at age 43 and showed stronger associations with age than in controls. WMH volume increased along the AD continuum, particularly in periventricular regions, and frontal, parietal, and occipital lobes. Associations were found with CSF biomarkers and temporo-parietal GM volumes.

DISCUSSION:

WMHs increase 10 years before AD symptom onset in DS and are closely linked with AD biomarkers and neurodegeneration. This suggests a direct connection to AD pathophysiology, independent of vascular risks. HIGHLIGHTS White matter hyperintensities (WMHs) increased 10 years before Alzheimer's disease symptom onset in Down syndrome (DS). WMHs were strongly associated in DS with the neurofilament light chain biomarker. WMHs were more associated in DS with gray matter volume in parieto-temporal areas.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imageamento por Ressonância Magnética / Biomarcadores / Síndrome de Down / Doença de Alzheimer / Substância Branca Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Alzheimers Dement Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imageamento por Ressonância Magnética / Biomarcadores / Síndrome de Down / Doença de Alzheimer / Substância Branca Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Alzheimers Dement Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha País de publicação: Estados Unidos